Combined usage of inhaled and intravenous milrinone in pulmonary hypertension after heart valve surgery.

Secondary pulmonary hypertension is a frequent condition after heart valve surgery. It may significantly complicate the perioperative management and increase patients' morbidity and mortality. The treatment has not been yet completely defined principally because of lack of the selectivity of drugs for the pulmonary vasculature. The usage of inhaled milrinone could be the possible therapeutic option. Inodilator milrinone is commonly used intravenously for patients with pulmonary hypertension and ventricular dysfunction in cardiac surgery. The decrease in systemic vascular resistance frequently necessitates concomitant use of norepinephrine. Pulmonary vasodilators might be more effective and also devoid of potentially dangerous systemic side effects if applied by inhalation, thus acting predominantly on pulmonary circulation. There are only few reports of inhaled milrinone usage in adult post cardiac surgical patients. We reported 2 patients with severe pulmonary hypertension after valve surgery. Because of desperate clinical situation, we decided to use the combination of inhaled and intravenous milrinone. Inhaled milrinone was delivered by means of pneumatic medication nebulizer dissolved with saline in final concentration of 0.5 mg/ml. The nebulizer was attached to the inspiratory limb of the ventilator circuit, just before the Y-piece. We obtained satisfactory reduction in mean pulmonary artery pressure in both patients, and they were successfully extubated and discharged. Although it is a very small sample of patients, we conclude that the combination of inhaled and intravenous milrinone could be an effective treatment of secondary pulmonary hypertension in high-risk cardiac valve surgery patient. The exact indications for inhaled milrinone usage, optimal concentrations for this route, and the beginning and duration of treatment are yet to be determined.

• Publication year

  2010

• Venue

  Collegium Antropologicum

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 20977113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Survival benefit of aortic valve replacement in patients with severe aortic regurgitation and pulmonary hypertension.

  2009cited by this paper
• One year efficacy and safety of oral sildenafil treatment in severe pulmonary hypertension.

  2009cited by this paper
• Aortic valve replacement in isolated severe aortic stenosis with left ventricular dysfunction: long-term survival and ventricular recovery.

  2009cited by this paper
• Preliminary experience with inhaled milrinone in cardiac surgery.

  2007cited by this paper
• Inhaled Milrinone: A New Alternative in Cardiac Surgery?

  2006cited by this paper
• Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients.

  2006cited by this paper
• Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates

  2005cited by this paper
• Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults.

  2005cited by this paper
• Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

  2004cited by this paper
• Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

  2004cited by this paper
• Haemodynamic evaluation of pulmonary hypertension

  2002cited by this paper
• Relation of pulmonary arterial diastolic and mean pulmonary arterial wedge pressures in patients with and without pulmonary hypertension.

  2001cited by this paper
• The Additive Pulmonary Vasodilatory Effects of Inhaled Prostacyclin and Inhaled Milrinone in Postcardiac Surgical Patients with Pulmonary Hypertension

  2001cited by this paper
• European system for cardiac operative risk evaluation (EuroSCORE).

  1999cited by this paper
• High-risk mitral valve replacement in severe pulmonary hypertension--30 years experience.

  1998cited by this paper
• A comparison of prostacyclin and sodium nitroprusside for the treatment of heart failure after cardiac surgery.

  1996cited by this paper
• Long-term outcome of cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension.

  1995cited by this paper
• Pulmonary deposition of a nebulised aerosol during mechanical ventilation.

  1993cited by this paper
• Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.

  1985cited by this paper

• Acute Right Ventricular Failure in Cardiac Surgery During Cardiopulmonary Bypass Separation: A Retrospective Case Series of 12 Years' Experience With Intratracheal Milrinone Administration.

  2019cites this paper
• Effet préventif de la milrinone inhalée chez les patients avec hypertension pulmonaire subissant une chirurgie cardiaque sous circulation extracorporelle : une approche pharmacométrique

  2016cites this paper
• A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients

  2016cites this paper
• Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders

  2015cites this paper
• Perioperative Pharmacological Management of Pulmonary Hypertensive Crisis during Congenital Heart Surgery

  2014cites this paper
• Pilot Randomized Controlled Trial of Inhaled Milrinone in High-Risk Cardiac Surgical Patients

  2014cites this paper
• Pharmacological Potential of PDE5 Inhibitors for the Treatment of Cystic Fibrosis

  2012cites this paper
• PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis

  2012cites this paper
• Pharmacological Potential of PDE 5 Inhibitors for the Treatment of Cystic Fibrosis

  2012cites this paper